Lumos Pharma

Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for rare diseases. Its product includes LUM-201, an oral growth hormone stimulating small molecule for the treatment of pediatric growth hormone deficiency (PGHD). The company was founded on June 4, 1999 and is headquartered in Austin, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Lumos Pharma excels in Q1 with FDA nod for LUM-201

Lumos Pharma's Q1 2024 earnings call showcased strong performance, financial stability, and promising updates on LUM-201, positioning the company for growth and success in the pharmaceutical industry.
While facing challenges in trial design, enrollment criteria, and funding, Lumos Pharma's innovative approach and positive market reception offer opportunities for market expansion and patient impact.
The call emphasized the potential advantages of LUM-201, the company's robust pipeline, and the importance of securing capital post-FDA trial design approval, setting the stage for future growth and development.

Lumos Pharma progresses LUM-201, seeks strategic partnerships for growth

Lumos Pharma's Q2 2024 performance reflects a strategic focus on advancing LUM-201 and managing costs.
Despite financial challenges and limited cash reserves, the company is leveraging opportunities for growth.
Engagement with Piper Sandler and positive trial data position Lumos Pharma for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AUSTIN, Texas, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on rare disorders, hosted two key opinion leaders (KOLs) in the field of pediatric endocrinology on December 6th to review the Company's interim data from two Phase 2 trials evaluating oral LUM-201 in moderate idiopathic Pediatric Growth Hormone Deficiency (iPGHD). Andrew Dauber, MD, MMSc, Chief of Endocrinology, Children's National Hospital, and Fernando Cassorla, MD, Chief of Pediatric Endocrinology, University of Chile, discussed recently released (on November 14, 2022) and new interim data (presented on December 6, 2022) from two ongoing OraGrowtH trials.

KOL Review of Lumos Pharma's Interim Phase 2 Data Supports Potential for New Oral Therapeutic Paradigm for Moderate Idiopathic PGHD Patients

AUSTIN, Texas, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on rare endocrine disorders, announced that the Company will host two key opinion leaders in the field of pediatric endocrinology for a discussion of interim data from our Phase 2 OraGrowtH210 and PK/PD OraGrowtH212 Trials evaluating oral LUM-201 in Pediatric Growth Hormone Deficiency (PGHD). The KOL webinar will take place on December 6th at 2:00 PM EST.

Lumos Pharma to Host KOL Webinar to Discuss Interim Phase 2 Data from OraGrowtH Trials in PGHD

AUSTIN, Texas, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials for Pediatric Growth Hormone Deficiency (PGHD), announced that the Company will present and host one-on-one meetings at the Piper Sandler 34th Annual Healthcare Conference November 29th through December 1st.

Lumos Pharma to Participate in the Piper Sandler 34th Annual Healthcare Conference

Lumos (LUMO) delivered earnings and revenue surprises of 14.85% and 24.25%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Lumos Pharma (LUMO) Reports Q3 Loss, Tops Revenue Estimates

-- Interim Data for Potentially the First Oral Medication for PGHD from Phase 2 OraGrowtH210 and PK/PD OraGrowtH212 Trials Met Expectations with an Encouraging Growth Response of 8.6 cm/yr at six months for the LUM-201 Dose of 1.6 mg/kg/day in the OraGrowtH210 Trial which Supports Advanced Planning for Pivotal Phase 3 Trial -- -- OraGrowtH210 Trial is ~80% enrolled and Primary Outcome Readout with all 80 Subjects at six months Anticipated 2H 2023 –

Lumos Pharma Reports Third Quarter 2022 Financial Results and Clinical Development Updates

- LUM-201, potentially the first oral medication for PGHD, met expectations in an interim analysis of two Phase 2 trials evaluating growth in Pediatric Growth Hormone Deficiency (PGHD) -

Lumos Pharma Announces Encouraging Interim Results from Two Phase 2 Trials Evaluating Oral LUM-201 for Moderate Pediatric Growth Hormone Deficiency

AUSTIN, Texas, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials for Pediatric Growth Hormone Deficiency (PGHD), announced that Lumos Pharma management will participate in a panel discussion and host one-on-one meetings at the Cantor Neurology & Psychiatry Conference in October.

Lumos Pharma to Participate in the Cantor Neurology & Psychiatry Conference

-- Plan to Repurchase Up to $3 Million of Common Shares -- AUSTIN, Texas, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (“The Company,” NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials for Pediatric Growth Hormone Deficiency (PGHD), today announced that its board of directors has authorized a share repurchase program to acquire up to $3 million of the Company's common stock. The Company may purchase common stock on the open market, through privately negotiated transactions, or otherwise, in compliance with the rules of the United States Securities and Exchange Commission and other applicable legal requirements. As of June 30, 2022, the Company had approximately $79.5 million of cash, cash equivalents, and marketable securities. The Company had approximately 8.4 million shares outstanding as of August 3, 2022.

Lumos Pharma Announces Share Repurchase Program

Lumos Pharma, Inc. (NASDAQ:LUMO ) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Lisa Miller - Senior Director of Investor Relations Richard Hawkins - Chairman and Chief Executive Officer Lori Lawley - Chief Financial Officer John McKew - President and Chief Scientific Officer David Karpf - Chief Medical Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald, L.P Emma Nesson - Piper Sandler & Co. Edward White - H.C. Wainwright & Co, LLC Catherine Novack - Jones Research Leland Gershell - Oppenheimer & Co. Inc. Elemer Piros - ROTH Capital Partners Operator Good afternoon, and welcome to Lumos Pharma's Second Quarter 2022 Results and Clinical Update Conference Call.

Lumos Pharma, Inc. (LUMO) CEO Richard Hawkins on Q2 2022 Results - Earnings Call Transcript

-- Continue to Anticipate Interim Data from Phase 2 OraGrowtH210 and PK/PD OraGrowtH212 Trials in Q4 2022 -- -- Primary Outcome Readouts from Both Trials Anticipated 2H 2023 with Data in up to 24 Patients Anticipated from OraGrowtH212 Trial --

Lumos Pharma Reports Second Quarter 2022 Financial Results and Clinical Development Updates

Lumos (LUMO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Lumos Pharma (LUMO) Expected to Beat Earnings Estimates: Should You Buy?

AUSTIN, Texas, July 27, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company, today announced it will report its second quarter 2022 financial results after market close on Tuesday, August 9, 2022. The company will host a conference call and webcast at 4:30 PM ET that day to discuss these financial results and provide an update on clinical and corporate activities. There will be a question-and-answer session following the prepared remarks.

Lumos Pharma to Report Second Quarter 2022 Financial Results and Host Conference Call on August 9, 2022

Lumos (LUMO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Lumos (LUMO) Soars 9.4%: Is Further Upside Left in the Stock?

AUSTIN, Texas, May 16, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the following upcoming investors conferences:

Lumos Pharma to Participate in Upcoming Investor Conferences

Lumos Pharma, Inc. (NASDAQ:LUMO ) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Lisa Miller - Senior Director, IR Richard Hawkins - CEO & Chairman John McKew - Chief Scientific Officer & President David Karpf - Chief Medical Officer Lori Lawley - CFO & Principal Accounting Officer Conference Call Participants Avraham Novick - Cantor Fitzgerald & Co. Yasmeen Rahimi - Piper Sandler & Co. Catherine Novack - JonesTrading Institutional Services Edward White - H.C. Wainwright & Co. Operator Good afternoon, and welcome to Lumos Pharma's First Quarter 2022 Results & Clinical Update Conference Call.

Lumos Pharma, Inc. (LUMO) CEO Richard Hawkins on Q1 2022 Results - Earnings Call Transcript

--Phase 2 OraGrowtH210 Trial Reached 50% Randomization Milestone – Interim Data from Phase 2 and PK/PD OraGrowtH Trials Anticipated by End of 2022-- --FDA Permits Treatment with LUM-201 Beyond 12 Months and Lifts Partial Clinical Hold--

Lumos Pharma Reports First Quarter 2022 Financial Results and Clinical Development Updates

The IND application for this pilot trial to evaluate oral growth hormone secretagogue, LUM-201, in NAFLD has been approved by the FDA The IND application for this pilot trial to evaluate oral growth hormone secretagogue, LUM-201, in NAFLD has been approved by the FDA

Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated Trial

AUSTIN, Tex., April 26, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company, today announced it will report its first quarter 2022 financial results after market close on Tuesday, May 10, 2022. The company will host a conference call and webcast at 4:30 PM ET that day to discuss these financial results and provide an update on clinical and corporate activities. There will be a question-and-answer session following the prepared remarks.

Lumos Pharma to Report First Quarter 2022 Financial Results and Host Conference Call on May 10, 2022

-   Interim Data Anticipated by End of 2022   -

Lumos Pharma Reaches 50% Randomization Milestone in Phase 2 OraGrowtH210 Trial Evaluating Oral LUM-201 in PGHD

AUSTIN, Texas, March 23, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that John McKew, PhD, President and Chief Scientific Officer of Lumos Pharma, will participate in a panel discussion at the Cantor Rare Disease Symposium at the end of March 2022.

Lumos Pharma to Participate in the Cantor Rare Disease Symposium

Lumos Pharma, Inc. (LUMO) CEO Rick Hawkins on Q4 2021 Results - Earnings Call Transcript

Data from interim analyses of Phase 2 OraGrowtH210 Trial and PK/PD OraGrowtH212 Trial evaluating oral LUM-201 in PGHD anticipated by the end of 2022 Data from interim analyses of Phase 2 OraGrowtH210 Trial and PK/PD OraGrowtH212 Trial evaluating oral LUM-201 in PGHD anticipated by the end of 2022

Lumos Pharma Reports Full Year 2021 Financial Results and Announces Plan to Perform Interim Analyses of OraGrowtH Trials

AUSTIN, Texas, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report its full year 2021 financial results after market close on Thursday, March 10, 2022. The company will host a conference call and webcast at 4:30 PM ET that day to discuss these financial results and provide an update on clinical and corporate activities. There will be a question-and-answer session following the prepared remarks.

Lumos Pharma to Report Full Year 2021 Financial Results and Host Conference Call on March 10, 2022

Lumos (LUMO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down 16.1% in 4 Weeks, Here's Why Lumos (LUMO) Looks Ripe for a Turnaround

The mean of analysts' price targets for Lumos (LUMO) points to a 190.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

News for Lumos Pharma Stock (LUMO)